1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Sanofi: Aubagio's tolerability profile is key differentiator in light of lacklustre efficacy

 
• By Sarah Nightingale

The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.

The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.

The TENERE study showed that the primary endpoints were not distinguishable and that the prevalence of adverse events was similar...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 
• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

More from Therapeutic Category

GSK’s Blenrep US Setback Could Go From Bad To Worse

 
• By Sushmita Panda

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.